Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

A notable finding is that audiences are split on whether they see more pharma ads in 2025 compared to 2024. Nearly half of ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

Shares of Eli Lilly & Co. rose 3.38% to $1,062.19 Monday, on what proved to be an all-around grim trading session for the ...

On Dec. 14, the season 1 finale of IT: Welcome to Derry premiered on HBO and HBO Max. The latest episode featured Pennywise ( ...

It’s a jam-packed schedule for Blue Angel pilots as they visit their show sites, ensuring everything is squared away ahead of ...

Orforglipron is Eli Lilly’s weight-loss pill, and Bank of America expects it to enter the market in the second half of 2026 ...

In today’s Pharmaceutical Executive Daily, Eli Lilly reports positive topline Phase III results for retatrutide, the FDA expands Amgen’s Uplizna label into generalized myasthenia gravis subtypes, and ...

Pennywise was always going to slither away for another 27-year slumber, but boy did he wave good-bye with gusto.

The survey showed that while most of the doctors didn’t have top-of-mind awareness of oral semaglutide’s upcoming FDA ...

Eli Lilly (NYSE: LLY) has outperformed the market over the past 5 years by 31.02% on an annualized basis producing an average annual return of 44.05%. Currently, Eli Lilly has a market capitalization ...